The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling

Matrix Biology

Volumn 35, Issue , 2014, Pages 112-122

  Lord, Megan S ^a   Chuang, Christine Y ^b,c   Melrose, James ^d   Davies, Michael J ^b,c   Iozzo, Renato V ^e   Whitelock, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c University of Sydney   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Endothelial cell; Extracellular matrix; Fibroblast growth factors; Glycosaminoglycan; Perlecan; Smooth muscle cell

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; LAMININ; MESSENGER RNA; PERLECAN; CHONDROITIN SULFATE; PRIMER DNA; PROTEOHEPARAN SULFATE; SIGNAL PEPTIDE;

ARTICLE; CELL ADHESION; CELL ADHESION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; ANALYSIS OF VARIANCE; CYTOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; METABOLISM; PHYSIOLOGY; TANDEM MASS SPECTROMETRY; VASCULAR SMOOTH MUSCLE;

ANALYSIS OF VARIANCE; CELL ADHESION; CELL PROLIFERATION; CHONDROITIN SULFATES; CHROMATOGRAPHY, LIQUID; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84901390292     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2014.01.016     Document Type: Article

References (76)

1. Aviezer D., Iozzo R.V., Noonan D.M., Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol. Cell. Biol. 1997, 17:1938-1946.
2. Benitz W.E., Kelley R.T., Anderson C.M., Lorant D.E., Bernfield M. Endothelial heparan sulfate proteoglycan I. Inhibitory effects on smooth muscle cell proliferation. Am. J. Respir. Cell Mol. Biol. 1990, 2:13-24.
3. Berry D., Shriver Z., Natke B., Kwan C.P., Venkataraman G. Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1. Biochem. J. 2003, 373:241-249.
4. Bingley J.A., Hayward I.P., Campbell J.H., Campbell G.R. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J. Vasc. Res. 1998, 28:308-318.
5. Bix G., Iozzo R.V. Novel interactions of perlecan: unraveling perlecan's role in angiogenesis. Microsc. Res. Tech. 2008, 71:339-348.
6. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., Zutter M.M., Santoro S.A., Kim J.K., Höök M., Reed C.C., Iozzo R.V. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J. Cell Biol. 2004, 166:97-107.
7. Bix G., Castello R., Burrows M., Zoeller J.J., Weech M., Iozzo R.A., Cardi C., Thakur M.L., Barker C.A., Camphausen K., Iozzo R.V. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 2006, 98:1634-1646.
8. Campbell J.H., Rennick R.E., Kalevitch S.G., Campbell G.R. Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype. Exp. Cell Res. 1992, 200:156-167.
9. Castellot J.J., Addonizio M.L., Rosenberg R., Karnowsky M.J. Cultured endothelial cells produced a heparinlike inhibitor of smooth muscle cell growth. J. Cell Biol. 1981, 90:372-379.
10. Chuang C.Y., Lord M.S., Melrose J., Rees M.D., Knox S.M., Freeman C., Iozzo R.V., Whitelock J.M. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49:5524-5532.
11. Clowes A.W., Clowes M.M. Kinetics of cellular proliferation after arterial injury II. Inhibition of smooth muscle growth by heparin. Lab. Invest. 1985, 52:611-616.
12. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265:625-626.
13. Costell M., Carmona R., Gustafsson E., Gonzalez-Iriarte M., Fässler R., Munoz-Chápuli R. Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ. Res. 2002, 91:158-164.
14. Farach-Carson M.C., Brown A.J., Lynam M., Safran J.B., Carson D.D. A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation. Matrix Biol. 2008, 27:150-160.
15. Farndale R.W., Buttle D.J., Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta 1986, 883:173-177.
16. Forsten K.E., Courant N.A., Nugent M.A. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J. Cell. Physiol. 1997, 172:209-220.
17. Garl P.J., Wenzlau J.M., Walker H.A., Whitelock J.M., Costell M., Weiser-Evans M.C. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ. Res. 2004, 94:175-183.
18. Ghiselli G., Chen J., Kaou M., Hallak H., Rubin R. Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells. Arterioscler. Thromb. Vasc. 2003, 23:1808-1813.
19. González-Iriarte M., Carmona R., Pérez-Pomares J.M., Macías D., Costell M., Munoz-Chápuli R. Development of the coronary arteries in a murine model of transposition of great arteries. J. Mol. Cell. Cardiol. 2003, 35:795-802.
20. Gustafsson E., Almonte-Becerril M., Bloch W., Costell M. Perlecan maintains microvessel integrity in vivo and modulates their formation in vitro. PLoS One 2013, 8:e53715.
21. Hedin U., Roy J., Tran P.K., Lundmark K., Rahman A. Control of smooth muscle cell proliferation - the role of the basement membrane. Thromb. Haemost. 1999, 82:23-26.
22. Hedin U., Roy J., Tran P.K. Control of smooth muscle cell proliferation in vascular disease. Curr. Opin. Lipidol. 2004, 15:559-565.
23. Heickendorff L. The basement membrane of arterial smooth muscle cells. APMIS 1989, S9:23-26.
24. Hughes S.E. Localisation and differential expression of the fibroblast growth factor (FGFR) multigene family in normal and atherosclerotic human arteries. Cardiovasc. Res. 1996, 32:557-569.
25. Iozzo R.V. Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 2005, 6:646-656.
26. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
27. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
28. Iozzo R.V., Zoeller J.J., Nyström A. Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol. Cell 2009, 27:503-513.
29. Ishijima M., Suzuki N., Hozumi K., Matsunobu T., Kosaki K., Kaneko H., Hassell J.R., Arikawa-Hirasawa E., Yamada Y. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol. 2012, 31:234-245.
30. Jung M., Lord M.S., Cheng B., Lyons J.G., Alkhouri H., Hughes J.M., McCarthy S.J., Iozzo R.V., Whitelock J.M. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: A role in angiogenesis and wound healing. J. Biol. Chem. 2013, 288:3289-3304.
31. Kadenhe-Chiweshe A., Papa J., McCrudden K.W., Frischer J., Bae J.O., Huang J., Fisher J., Lefkowitch J.H., Feirt N., Rudge J., Holash J., Yancopoulos G.D., Kandel J.J., Yamashiro D.J. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol. Cancer Res. 2008, 6:1-9.
32. Kaneko H., Ishijima M., Futami I., Tomikawa-Ichikawa N., Kosaki K., Sadasuki R., Yamada Y., Kurosawa H., Kaneko H., Arikawa-Hirasawa E. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol. 2013, 32:178-187.
33. Kinsella M.G., Tran P.K., Weiser-Evans M.C.M., Reidy M., Majack R.A., Wight T.N. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler. Thromb. Vasc. 2003, 23:608-614.
34. Kirn-Safran C.B., Gomes R.R., Brown A.J., Carson D.D. Heparan sulfate proteoglycans: coordinators of multiple signaling pathways during chondrogenesis. Birth Defects Res. C Embryo Today 2004, 72:69-88.
35. Knox S., Melrose J., Whitelock J. Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins. Proteomics 2001, 1:1534-1541.
36. Knox S., Merry C., Stringer S., Melrose J., Whitelock J. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J. Biol. Chem. 2002, 277:14657-14665.
37. Knox S., Fosang A.J., Last K., Melrose J., Whitelock J. Perlecan from human epithelial cells is a hybrid heparan/chondroitin/keratan sulfate proteoglycan. FEBS Lett. 2005, 579:5019-5023.
38. Koyama H., Reidy M. Reinjury of arterial lesions induces intimal smooth muscle cell replication that is not controlled by fibroblast growth factor 2. Circ. Res. 1997, 80:408-417.
39. Kvist A.J., Johnson A.E., Mörgelin M., Gustafsson E., Bengtsson E., Lindblom K., Aszódi A., Fässler R., Sasaki T., Timpl R., Aspberg A. Chondroitin sulfate perelcan enhances collagen fibril formation. Implications for perlecan chondrodysplasias. J. Biol. Chem. 2006, 281:33127-33139.
40. Lindner V., Reidy M. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3739-3743.
41. Lindner V., Lappi D.A., Baird A., Majack R.A., Reidy M.A. Role of fibroblast growth factor in vascular lesion formation. Circ. Res. 1991, 68:106-113.
42. Lord M.S., Cheng B., McCarthy S.J., Jung M., Whitelock J.M. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins. Biomaterials 2011, 32:6655-6662.
43. Lundmark K., Tran P.K., Kinsella M.G., Clowes A.W., Wight T.N., Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J. Cell. Physiol. 2001, 188:67-74.
44. Melrose J., Smith S., Ghosh P., Whitelock J. Perlecan, the multidomain heparan sulfate proteoglycan of basement membranes, is also a prominent component of the cartilaginous primordia in the developing human fetal spine. J. Histochem. Cytochem. 2003, 51:1331-1341.
45. Melrose J., Smith S., Cake M., Read R., Whitelock J. Spatial and temporal immunolocalisation of perlecan in the ovine meniscus. Histochem. Cell Biol. 2005, 124:225-235.
46. Melrose J., Roughley P., Knox S., Smith S., Lord M., Whitelock J. The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J. Biol. Chem. 2006, 281:36905-36914.
47. Melrose J., Hayes A.J., Whitelock J.M., Little C.B. Perlecan, the "jack of all trades" proteoglycan of cartilaginous weight-bearing connective tissues. Bioessays 2008, 30:457-469.
48. Mongiat M., Sweeney S., San Antonio J.D., Fu J., Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278:4238-4249.
49. Nugent M.A., Iozzo R.V. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32:115-120.
50. Nugent M.A., Karnowsky M.J., Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ. Res. 1993, 73:1051-1060.
51. Nugent M.A., Nugent H.M., Iozzo R.V., Sanchack K., Edelman E.R. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6722-6727.
52. Olson N.E., Chao S., Lindner V., Reidy M.A. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am. J. Pathol. 1992, 140:1017-1023.
53. Ornitz D.M., Yayon A., Flanagan J.G., Svahn C.M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 1992, 12:240-247.
54. Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., Gao G., Goldfarb M. Receptor specificity of the fibroblast growth family. J. Biol. Chem. 1996, 271:15292-15297.
55. Plaas A.H.K., Wong-Palms S., Roughley P.J., Midura R.J., Hascall V.C. Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan. J. Biol. Chem. 1997, 272:20603-20610.
56. Sharma B., Handler M., Eichstetter I., Whitelock J., Nugent M.A., Iozzo R.V. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J. Clin. Invest. 1998, 102:1599-1608.
57. Skinner M.P., Raines E.W., Ross P. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am. J. Pathol. 1994, 145:1070-1081.
58. Soulez M., Pilon E.A., Dieudé M., Cardinal H., Brassard N., Qi S., Wu S.J., Durocher Y., Madore F., Perreault C., Hébert M.J. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ. Res. 2012, 110:94-104.
59. Speir E., Sasse J., Shtivastav S., Casscells W. Culture-induced increase of acidic and basic fibroblast growth factor activities and their association with the nuclei of vascular endothelial and smooth muscle cells. J. Cell. Physiol. 1991, 147:362-373.
60. Thyberg J., Blomgren K., Roy J., Tran P.K., Hedin U. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J. Histochem. Cytochem. 1997, 45:837-846.
61. Tran P.K., Tran-Lundmark K., Soininen R., Tryggvason K., Thyberg J., Hedin U. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ. Res. 2004, 94:550-558.
62. Underwood P.A., Mitchell S., Whitelock J.M. Heparin fails to inhibit the proliferation of human vascular smooth muscle cells in the presence of human serum. J. Vasc. Res. 1998, 35:449-460.
63. Walker H.A., Whitelock J.M., Garl P.J., Nemenoff R.A., Stenmark K.R., Weiser-Evans M.C.M. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol. Biol. Cell 2003, 14:1941-1952.
64. Weich H.A., Iberg N., Klagsbrun M., Folkman J. Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. Growth Factors 1990, 2:313-320.
65. Weiser M.C.M., Belknap J.K., Grieshaber S.S., Kinsella M.G., Majack R.A. Developmental regulation of perlecan gene expression in aortic smooth muscle cells. Matrix Biol. 1996, 15:331-340.
66. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem. Rev. 2005, 105:2745-2764.
67. Whitelock J., Mitchell S., Underwood P.A. The effect of human endothelial cell-derived proteoglycans on human smooth muscle cell growth. Cell Biol. Int. 1997, 21:181-189.
68. Whitelock J.M., Graham L.D., Melrose J., Murdoch A.D., Iozzo R.V., Underwood P.A. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 1999, 18:163-178.
69. Whitelock J.M., Melrose J., Iozzo R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
70. Willis C.D., Schaefer L., Iozzo R.V. The biology of perlecan and its bioactive modules. Extracellular Matrix: Pathobiology and Signaling 2012, 171-184. Walter de Gruyter GmbH & Co. KG, Berlin. N.K. Karamanos (Ed.).
71. Wilusz R.E., DeFrate L.E., Guilak F. A biomechanical role for perlecan in the pericellular matrix of articular carrtilage. Matrix Biol. 2012, 31:320-327.
72. Winkles J.A., Friesel R., Burgess W.H., Howk R., Mehlman T., Weinstein R., Maciag T. Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial cell growth factor). Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7124-7128.
73. Woodall B.P., Nyström A., Iozzo R.A., Eble J.A., Niland S., Krieg T., Eckes B., Pozzi A., Iozzo R.V. Integrin a2b1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283:2335-2343.
74. Yamamoto C., Wakata T., Fujiwara Y., Kaji T. Induction of synthesis of a large heparan sulfate proteoglycan, perlecan, by thrombin in cultured human coronary smooth muscle cells. Biochim. Biophys. Acta 2005, 1722:92-102.
75. Zoeller J.J., McQuillan A., Whitelock J., Ho S.-Y., Iozzo R.V. A central function for perlecan in skeletal muscle and cardiovascular development. J. Cell Biol. 2008, 181:381-394.
76. Zoeller J.J., Whitelock J., Iozzo R.V. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol. 2009, 28:284-291.